Genomic  ||| S:0 E:8 ||| JJ
strategies  ||| S:8 E:19 ||| NNS
to  ||| S:19 E:22 ||| TO
improve  ||| S:22 E:30 ||| VB
outcome  ||| S:30 E:38 ||| NN
and  ||| S:38 E:42 ||| CC
individualize  ||| S:42 E:56 ||| JJ
therapy  ||| S:56 E:64 ||| NN
in  ||| S:64 E:67 ||| IN
cancer ||| S:67 E:73 ||| NN
:  ||| S:73 E:75 ||| :
the  ||| S:75 E:79 ||| DT
paradigm  ||| S:79 E:88 ||| NN
of  ||| S:88 E:91 ||| IN
childhood  ||| S:91 E:101 ||| FW
acute  ||| S:101 E:107 ||| FW
lymphoblastic  ||| S:107 E:121 ||| FW
leukemia  ||| S:121 E:130 ||| FW
Childhood  ||| S:130 E:140 ||| FW
acute  ||| S:140 E:146 ||| FW
lymphoblastic  ||| S:146 E:160 ||| FW
leukemia  ||| S:160 E:169 ||| FW
( ||| S:169 E:170 ||| -LRB-
ALL ||| S:170 E:173 ||| NNP
)  ||| S:173 E:175 ||| -RRB-
is  ||| S:175 E:178 ||| VBZ
the  ||| S:178 E:182 ||| DT
classic  ||| S:182 E:190 ||| JJ
example  ||| S:190 E:198 ||| NN
for  ||| S:198 E:202 ||| IN
a  ||| S:202 E:204 ||| DT
drug-responsive  ||| S:204 E:220 ||| JJ
malignancy ||| S:220 E:230 ||| NN
,  ||| S:230 E:232 ||| ,
and  ||| S:232 E:236 ||| CC
contemporary  ||| S:236 E:249 ||| JJ
risk-directed  ||| S:249 E:263 ||| JJ
therapies  ||| S:263 E:273 ||| NNS
cure  ||| S:273 E:278 ||| VB
more  ||| S:278 E:283 ||| JJR
than  ||| S:283 E:288 ||| IN
80 ||| S:288 E:290 ||| CD
%  ||| S:290 E:292 ||| NN
of  ||| S:292 E:295 ||| IN
children  ||| S:295 E:304 ||| NNS
with  ||| S:304 E:309 ||| IN
ALL  ||| S:309 E:313 ||| NNP
in  ||| S:313 E:316 ||| IN
industrialized  ||| S:316 E:331 ||| JJ
countries ||| S:331 E:340 ||| NNS
.  ||| S:340 E:342 ||| .
Antileukemic  ||| S:342 E:355 ||| JJ
medications ||| S:355 E:366 ||| NN
,  ||| S:366 E:368 ||| ,
however ||| S:368 E:375 ||| RB
,  ||| S:375 E:377 ||| ,
can  ||| S:377 E:381 ||| MD
cause  ||| S:381 E:387 ||| VB
significant  ||| S:387 E:399 ||| JJ
adverse  ||| S:399 E:407 ||| JJ
drug  ||| S:407 E:412 ||| NN
reactions ||| S:412 E:421 ||| NNS
.  ||| S:421 E:423 ||| .
Moreover ||| S:423 E:431 ||| RB
,  ||| S:431 E:433 ||| ,
some  ||| S:433 E:438 ||| DT
children  ||| S:438 E:447 ||| NNS
have  ||| S:447 E:452 ||| VBP
leukemia  ||| S:452 E:461 ||| JJ
cell  ||| S:461 E:466 ||| NN
clones  ||| S:466 E:473 ||| NNS
which  ||| S:473 E:479 ||| WDT
are  ||| S:479 E:483 ||| VBP
resistant  ||| S:483 E:493 ||| VBN
to  ||| S:493 E:496 ||| TO
current  ||| S:496 E:504 ||| JJ
antileukemic  ||| S:504 E:517 ||| JJ
treatment ||| S:517 E:526 ||| NN
.  ||| S:526 E:528 ||| .
As  ||| S:528 E:531 ||| IN
ALL  ||| S:531 E:535 ||| NNP
is  ||| S:535 E:538 ||| VBZ
still  ||| S:538 E:544 ||| RB
among  ||| S:544 E:550 ||| IN
the  ||| S:550 E:554 ||| DT
leading  ||| S:554 E:562 ||| JJ
causes  ||| S:562 E:569 ||| NNS
of  ||| S:569 E:572 ||| IN
death  ||| S:572 E:578 ||| NN
from  ||| S:578 E:583 ||| IN
disease  ||| S:583 E:591 ||| NN
in  ||| S:591 E:594 ||| IN
children  ||| S:594 E:603 ||| NNS
aged  ||| S:603 E:608 ||| VBN
one  ||| S:608 E:612 ||| CD
to  ||| S:612 E:615 ||| TO
15  ||| S:615 E:618 ||| CD
years ||| S:618 E:623 ||| NNS
,  ||| S:623 E:625 ||| ,
further  ||| S:625 E:633 ||| JJ
improvement  ||| S:633 E:645 ||| NN
of  ||| S:645 E:648 ||| IN
childhood  ||| S:648 E:658 ||| NN
ALL  ||| S:658 E:662 ||| NNP
therapy  ||| S:662 E:670 ||| NN
is  ||| S:670 E:673 ||| VBZ
urgently  ||| S:673 E:682 ||| RB
needed ||| S:682 E:688 ||| VBN
.  ||| S:688 E:690 ||| .
The  ||| S:690 E:694 ||| DT
aim  ||| S:694 E:698 ||| NN
of  ||| S:698 E:701 ||| IN
pharmacogenomics  ||| S:701 E:718 ||| NN
is  ||| S:718 E:721 ||| VBZ
to  ||| S:721 E:724 ||| TO
elucidate  ||| S:724 E:734 ||| VB
functionally  ||| S:734 E:747 ||| JJ
relevant  ||| S:747 E:756 ||| JJ
genomic  ||| S:756 E:764 ||| JJ
determinants  ||| S:764 E:777 ||| NN
for  ||| S:777 E:781 ||| IN
drug  ||| S:781 E:786 ||| NN
disposition  ||| S:786 E:798 ||| NN
and  ||| S:798 E:802 ||| CC
response  ||| S:802 E:811 ||| NN
in  ||| S:811 E:814 ||| IN
order  ||| S:814 E:820 ||| NN
to  ||| S:820 E:823 ||| TO
optimize  ||| S:823 E:832 ||| VB
drug  ||| S:832 E:837 ||| NN
therapy  ||| S:837 E:845 ||| NN
based  ||| S:845 E:851 ||| VBN
on  ||| S:851 E:854 ||| IN
a  ||| S:854 E:856 ||| DT
patient ||| S:856 E:863 ||| NN
's  ||| S:863 E:866 ||| POS
genomic  ||| S:866 E:874 ||| JJ
profile ||| S:874 E:881 ||| NN
.  ||| S:881 E:883 ||| .
Pharmacogenomics  ||| S:883 E:900 ||| NNP
has  ||| S:900 E:904 ||| VBZ
evolved  ||| S:904 E:912 ||| VBN
from  ||| S:912 E:917 ||| IN
the  ||| S:917 E:921 ||| DT
study  ||| S:921 E:927 ||| NN
of  ||| S:927 E:930 ||| IN
single  ||| S:930 E:937 ||| JJ
candidate  ||| S:937 E:947 ||| NN
genes  ||| S:947 E:953 ||| NNS
to  ||| S:953 E:956 ||| TO
large-scale  ||| S:956 E:968 ||| JJ
genome-wide  ||| S:968 E:980 ||| JJ
strategies ||| S:980 E:990 ||| NNS
.  ||| S:990 E:992 ||| .
Results  ||| S:992 E:1000 ||| NNS
from  ||| S:1000 E:1005 ||| IN
recent  ||| S:1005 E:1012 ||| JJ
pharmacogenomic  ||| S:1012 E:1028 ||| JJ
investigations  ||| S:1028 E:1043 ||| NNS
in  ||| S:1043 E:1046 ||| IN
children  ||| S:1046 E:1055 ||| NNS
with  ||| S:1055 E:1060 ||| IN
ALL  ||| S:1060 E:1064 ||| NNP
hold  ||| S:1064 E:1069 ||| NN
promise  ||| S:1069 E:1077 ||| NN
to  ||| S:1077 E:1080 ||| TO
improve  ||| S:1080 E:1088 ||| VB
ALL  ||| S:1088 E:1092 ||| JJ
therapy  ||| S:1092 E:1100 ||| NN
in  ||| S:1100 E:1103 ||| IN
the  ||| S:1103 E:1107 ||| DT
near  ||| S:1107 E:1112 ||| JJ
future ||| S:1112 E:1118 ||| NN
;  ||| S:1118 E:1120 ||| :
and  ||| S:1120 E:1124 ||| CC
can  ||| S:1124 E:1128 ||| MD
serve  ||| S:1128 E:1134 ||| VB
as  ||| S:1134 E:1137 ||| IN
a  ||| S:1137 E:1139 ||| DT
model  ||| S:1139 E:1145 ||| NN
to  ||| S:1145 E:1148 ||| TO
improve  ||| S:1148 E:1156 ||| VB
drug  ||| S:1156 E:1161 ||| NN
therapy  ||| S:1161 E:1169 ||| NN
in  ||| S:1169 E:1172 ||| IN
other  ||| S:1172 E:1178 ||| JJ
malignancies  ||| S:1178 E:1191 ||| NN
as  ||| S:1191 E:1194 ||| IN
well ||| S:1194 E:1198 ||| RB
.  ||| S:1198 E:1200 ||| .
